The results of the QUO VADIS trial are very exciting.
An earlier report was presented at the 1998 American College of Cardiology meeting on Part A, the mechanistic arm of the QUO VADIS study.
Part B of the QUO VADIS study was a randomized, double-blind, placebo-controlled trial designed to evaluate the clinical effects of quinapril hydrochloride (ACCUPRIL(R)) therapy on ischemia in patients who underwent bypass surgery.
In QUO VADIS, baseline characteristics of both treatment groups were comparable, including ischemic ST segment changes and exercise duration.
QUO VADIS has been offering its expertise to executives at struggling corporations with at least 300 employees by providing free confidential consultations that evaluate their current brand marketing strategies and assets.
QUO VADIS is an award-winning, revenue growth focused brand communications practice that creates distinctive Web, film, television, radio, and print assets for the finest brands in the world.